P450-catalyzed asymmetric cyclopropanation of electron-deficient olefins under aerobic conditions

Hans Renata, Z. Jane Wang, Rebekah Z. Kitto

and Frances H. Arnold*

Contribution from the Division of Chemistry and Chemical Engineering, California Institute of Technology

1200 E California Blvd, MC 210-41, Pasadena, California 91125

SUPPLEMENTARY MATERIAL

Table of Contents

Materials and Methods............................................................................................page SI-2
General Procedures ............................................................................................page SI-3
Calibration of Cyclopropanation Products............................................................page SI-4
Amino Acid Sequences.....................................................................................page SI-7
General Procedures for Synthesis of Acrylamides 5a–5g ....................................page SI-8
General Procedures for Synthesis of Acrylamides 7a–7e....................................page SI-9
Preparative Scale Whole Cell Aerobic Reactions.................................................page SI-11
Characterization Data for Cyclopropanes.............................................................page SI-11
References........................................................................................................page SI-16
NMR Spectra of Compounds..............................................................................page SI-17–45
Materials and Methods

Unless otherwise noted, all chemicals and reagents for chemical reactions were obtained from commercial suppliers (Sigma-Aldrich, Acros) and used without further purification. Silica gel chromatography purifications were carried out using AMD Silica Gel 60, 230-400 mesh. $^1$H and $^{13}$C NMR spectra were recorded on either a Varian Mercury 300 spectrometer (300 MHz and 75 MHz, respectively) or a Varian Inova 500 MHz (500 MHz and 126 MHz, respectively) and are internally referenced to residual solvent peak for chloroform. Data for $^1$H NMR are reported in the conventional form: chemical shift ($\delta$ ppm), multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad), coupling constant (Hz), integration. High-resolution mass spectra were obtained with a JEOL JMS-600H High Resolution Mass Spectrometer at the California Institute of Technology Mass Spectral Facility. Reactions were monitored using thin layer chromatography (Merck 60 silica gel plates) using an UV light for visualization and an acidic mixture of anisaldehyde, phosphomolybdic acid, or ceric ammonium molybdate, or basic aqueous KMnO$_4$ as developing agents. Gas chromatography (GC) analyses were carried out using a Shimadzu GC-17A gas chromatograph with FID detector and J&W HP-5 column (30 m x 0.32 mm, 0.25 µm film) and 2-phenylethanol as an internal standard. Gas chromatography mass spectrometry (GC-MS) analyses were carried out using a Shimadzu TQ8030 GC-MS with ion count detector and J&W HP-5 column (30 m x 0.32 mm, 0.25 µM film). Analytical SFC was performed with a Mettler SFC supercritical CO$_2$ analytical chromatography system utilizing Chiralpak AS column or OD column (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. Semi-preparative HPLC was performed using an Agilent 1200 series, a UV detector, and an Agilent XDB-C18 column (9.4 mm x 250 mm, 5 µm).

Plasmids pCWori[BM3] and pET22 were used as cloning vectors. Site-directed mutagenesis was accomplished by a modified Quikchange protocol using primers bearing desired mutations (IDT, San Diego, CA). Restriction enzymes BamHI, EcoRI, XhoI, Phusion polymerase, and T4 ligase were purchased from New England Biolabs (NEB, Ipswich, MA).
**General Procedures**

**CO binding assay.** CO assay was used to determine the concentration in crude lysate. Cells were lysed by sonication and two cuvettes containing crude lysate with hemoprotein of unknown concentration were prepared. Carbon monoxide was gently bubbled through one solution for 30 seconds and Na$_2$S$_2$O$_4$ (<2 mg) was added immediately. Na$_2$S$_2$O$_4$ (2 mg) was added to the other cuvette as well and both were sealed with parafilm. Hemoprotein concentration was determined from ferrous CO binding difference spectrum between the two samples using extinction coefficients of $\epsilon_{422-490} = 180$ mM$^{-1}$ cm$^{-1}$ for histidine-ligated BM3.$^1$

**Small scale whole cell reactions.** *E. coli* (BL21) cells coding for appropriate enzyme variant were grown from glycerol stock overnight (37 °C, 250 rpm) in 5 ml TB$_{amp}$. The pre-culture was used to inoculate 45 mL of Hyperbroth medium (1 L Hyperbroth prepared from powder from AthenaES©, 0.1 mg mL$^{-1}$ ampicillin) in a 125 mL Erlenmeyer flask and this culture was incubated at 37 °C, 200 rpm for approximately 3 h. At OD$_{600} = 1.8$, the cultures were cooled to 22 °C and the shaking was reduced to 140 rpm before inducing with IPTG (0.25 mM) and $\delta$-aminolevulinic acid (0.50 mM). Cultures were harvested after 20 h and resuspended in nitrogen-free M9-N medium (1 L: 31 g Na$_2$HPO$_4$, 15 g KH$_2$PO$_4$, 2.5 g NaCl, 0.24 g MgSO$_4$, 0.010 g CaCl$_2$) until the indicated OD$_{600}$ (usually OD$_{600} = 60$) is obtained. Aliquots of the cell suspension were used for determination of the enzyme expression level (2–3 mL) after lysis.

**Anaerobic conditions:** *E. coli* cells (OD$_{600} = 60$) were transferred to a crimped 6 mL vial and made anaerobic by degassing with argon for 5-10 min. In parallel, glucose (50 μL, 250 mM) was added to 2 mL crimp vials that are sealed. The headspaces of these vials were purged with argon for 5-10 min. If multiple reactions were being carried out in parallel, a maximum of 8 vials were connected via cannulae and degassed in series. Cells (425 μL) were transferred to each vial via syringe and the olefin substrate was added (12.5 μL of a 800 mM solution of styrene in EtOH or a 400 mM solution of acrylamide 1 in EtOH), followed by EDA (12.5 μL of a 350 mM or 400 mM solution in EtOH). The reactions were shaken on a table-top shake plate at room temperature for 5 h. The reactions were quenched by addition of 25 μL of 3 M HCl, followed by 20 μL of the internal standard (20 mM 2-phenylethanol solution in cyclohexane) and 1 mL cyclohexane. The mixture was transferred to a 2 mL Eppendorf tube, vortexed and then centrifuged (10,000x rcf, 30 s). The organic layer was removed and analyzed by GC to determine yield and chiral SFC to determine enantioselectivity.
Aerobic conditions: Cell suspension was used without sparging with argon. Cells (425 μL, OD$_{600}$ = 60) and glucose (50 μL, 250 mM) were combined in an unsealed 2 mL glass vial. The olefin substrate was added (12.5 μL, 400 mM in EtOH), followed by EDA (12.5 μL, 400 mM in EtOH). The vial was covered with foil then shaken at 35 rpm for 5 h. The reactions were quenched by addition of 25 μL of 3 M HCl, followed by 20 μL of the internal standard (20 mM 2-phenylethanol solution in cyclohexane) and 1 mL cyclohexane. The mixture was transferred to a 2 mL Eppendorf tube, vortexed and then centrifuged (10,000x rcf, 30 s). The organic layer was removed and analyzed by GC to determine yield and chiral SFC to determine enantioselectivity.

Analysis of crude reaction mixture: GC analysis of product was performed using J&W HP-5 column (30 m x 0.32 mm, 0.25 μM film) with the method 90 °C hold 2 min, 90–110 at 6 °C/min, 110–190 at 40 °C/min, 190–300 at 20 °C/min, 300 °C hold 1 min, 12.8 min total): internal standard (3.55 min), retention times for the cis and trans products are listed in the characterization section below. Analytical SFC of product was performed on either Chiralpak AS column or OD column, eluting with iPrOH at 2.5 mL/min and detecting at 210 nm. Semi-preparative HPLC for all products was performed on 9.4 mm x 250 mm, 5 μm Agilent XDB-C18 column, detection at 210 nm, flow rate 3.0 mL/min, H$_2$O/MeCN, gradient: 0 min 10% MeCN, 30 min 70% MeCN, hold 5 min, 40 min 95% MeCN

Calibration of Cyclopropanation Products

Yields of cyclopropanation products were determined using calibration curves made with independently synthesized standards. Stock solutions of product were made at 120 or 160 mM in DMSO. To 4 samples containing cells at OD$_{600}$ = 60, product was added from either of the stock solutions such that a final concentration of 1.5-6.0 or 2.0-8.0 mM product was obtained. Additional DMSO was added such that the total volume of organics added to each tube was 25 μL. Next, 20 μL of a 20 mM stock solution of internal standard in cyclohexane was added to each Eppendorf tube, followed by 1 mL of cyclohexane. The Eppendorf tubes were vortexed and centrifuged (13,000 x rcm, 30 seconds). The organic layer was then analyzed by GC using J&W HP-5 column (30 m x 0.32 mm, 0.25 μM film: 90 °C hold 2 min, 90-110 at 6 °C/min, 110-190 at 40 °C/min, 190–300 at 20 °C/min, 300 °C hold 1 min, 12.8 min total). The ratio of the areas under the internal standard and product peaks was plotted against the concentration for each solution (1.5 to 6.0 mM or 2.0 to 8.0 mM).
**Amino Acid Sequences**

**Table S1.** List of mutations in enzyme variants, relative to wild type BM3 holoprotein (WT). All mutations listed below are for the heme domain. There are no mutations present in the reductase domain relative to wild type.

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Amino acid substitution with respect to WT</th>
</tr>
</thead>
<tbody>
<tr>
<td>T268A-AxH</td>
<td>T268A, C400H</td>
</tr>
<tr>
<td>BM3-HStar</td>
<td>V78M, L181V, T268A, C400H, L437W</td>
</tr>
</tbody>
</table>

The amino acid sequence for WT (holoprotein) is as follows:

```
>SEQ ID NO:1: gi|142798|gb|AAA87602.1| cytochrome P-450:NADPH-P-450 reductase precursor [Bacillus megaterium]
MTIKEMPQPKTGELKNLPLNTDKVPQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRSFKDNSQALKRHF
FVRFDFAGDFLTSWHENKWKAHONILFSFSQAMKRYHAMVVDIAVQLVQKWEILNADEHEIVPEDMRSTLTDITL
GLCGFNYRFSYRDPQHPITSMVRALDEANMLKLQRANPDDPAYDENKRQFQEDIKVMDLVDKTIADKAGSEQSM
DDLITHMNLNGKDPETGPDLDENRYQTFLLIAGHTTSGGLSFLAYLFVKNHPVHQAAEAEAARVLVDVPVSYKQ
VKQPKYGMVLNEALRWPTAPAFSLYAIEDTVLQuéYPLEKDELMLVILQPLHRDKTMGDDVEEFPRPERFNPSA
IPQHAKPFNGQNGAICGQFGAFHEALVLQGMLKHDFEDHTYNEIETLTKPEGFVAKSKKIPILGIPS
STEQSAKKVRKKAENHNPFLVLYGSMNMTAEGERDLDIALAAMSKGFAVQFVYLDHSNALPREGAVLTVTASYNG
HPDNDAKQKFDWLQDASADEVEKGVVRSVFGCDKNWATTYKQVPAFIDETLAARKGAENIADRGEDASDDFEGTY
EREHMWSDYAVYNYLNDENSEDKSTLQFVDFSDAAMPLAMKGMASFTNVASKELPQPSARSHRLIELPKEA
SYQEGDHDLGVIPFRNYEGTVNRVTFRGDLASQQIREALEEEEKLAHLPLAKTSVSEELYYYEQLDVPDVRTRQLAMAA
KTVCPHKVLELEELKEKQAMYKVLKRLTMLEELKEKYPASEMKSFESTFALLPSRPRYESSISSPRVDDFQKAST
SVSVSASEWSQYEGYKGAASNILALQEDQGDITCFISTQPSQHSTLPKDPETPLMVGPGVFRPFQVQARKLQEKS
QGSLEGAEHYLFCCRSPHEDLYLQELEANAOQSEGILITLHTAFAFRPMQNPKYTVQHVEQDGKLLIELLDQGAHYFC
DGSQMAPAVEATLMKSYADHVQVESDAWARLWLQOLEEKGRYKAVDHWAGHHHHH
```

The nucleotide sequence for WT (holoprotein) is as follows:

```
ATGACAATTTAAAAGAATGCTTCCACCCAAACAGTTTGGAGAGCTTTAAAAATTTACCCTTATTAAACACAGATAAAC
GCTTGACTTTGTGATGAAAAATTGCCTGATGAAATTAGAGAAATCTTTAAATCTCGAGCGCTTGTGTCGATACGC
GCTACTTATACGAATGGCTCTAATAAATAGATGTGCGTGTAAATGCGATGCGTGATAACCGTCTAATTCGATGA
TTTCTGATTTTGACCGAGACCGGTTTTATTATACGGTGGATGAAAAAGCTTTAAACAGCTGGTGGATGAAAAC
CTTACTTCCAATCTCAGTGCAGCGCTCTTTAGTAAAACCGTCTGACGATGCGTACAACCTTTTAATTACGGT
GCTGTTTTGTACCGGTCTTATTTACCAGTTTACGGAAGCAGCTCTTATGGAAGGATGCTGAAAGCAGCTCTT
GGCTCTTATATTCTCAGTGATGAGGTGCTTAAATACCGTACGCTGAAGCAGCTCTTATGGAAGGAGTCTG
```

The nucleotide sequence for mutants (holoprotein) is as follows:

```
ATGACAATTTAAAAGAATGCTTCCACCCAAACAGTTTGGAGAGCTTTAAAAATTTACCCTTATTAAACACAGATAAAC
GCTTGACTTTGTGATGAAAAATTGCCTGATGAAATTAGAGAAATCTTTAAATCTCGAGCGCTTGTGTCGATACGC
GCTACTTATACGAATGGCTCTAATAAATAGATGTGCGTGTAAATGCGATGCGTGATAACCGTCTAATTCGATGA
TTTCTGATTTTGACCGAGACCGGTTTTATTATACGGTGGATGAAAAAGCTTTAAACAGCTGGTGGATGAAAAC
CTTACTTCCAATCTCAGTGCAGCGCTCTTTAGTAAAACCGTCTGACGATGCGTACAACCTTTTAATTACGGT
GCTGTTTTGTACCGGTCTTATTTACCAGTTTACGGAAGCAGCTCTTATGGAAGGATGCTGAAAGCAGCTCTT
GGCTCTTATATTCTCAGTGATGAGGTGCTTAAATACCGTACGCTGAAGCAGCTCTTATGGAAGGAGTCTG
```

The nucleotide sequence for BM3-HStar (holoprotein) is as follows:

```
ATGACAATTTAAAAGAATGCTTCCACCCAAACAGTTTGGAGAGCTTTAAAAATTTACCCTTATTAAACACAGATAAAC
GCTTGACTTTGTGATGAAAAATTGCCTGATGAAATTAGAGAAATCTTTAAATCTCGAGCGCTTGTGTCGATACGC
GCTACTTATACGAATGGCTCTAATAAATAGATGTGCGTGTAAATGCGATGCGTGATAACCGTCTAATTCGATGA
TTTCTGATTTTGACCGAGACCGGTTTTATTATACGGTGGATGAAAAAGCTTTAAACAGCTGGTGGATGAAAAC
CTTACTTCCAATCTCAGTGCAGCGCTCTTTAGTAAAACCGTCTGACGATGCGTACAACCTTTTAATTACGGT
GCTGTTTTGTACCGGTCTTATTTACCAGTTTACGGAAGCAGCTCTTATGGAAGGATGCTGAAAGCAGCTCTT
GGCTCTTATATTCTCAGTGATGAGGTGCTTAAATACCGTACGCTGAAGCAGCTCTTATGGAAGGAGTCTG
```

The nucleotide sequence for T268A-AxH (holoprotein) is as follows:

```
ATGACAATTTAAAAGAATGCTTCCACCCAAACAGTTTGGAGAGCTTTAAAAATTTACCCTTATTAAACACAGATAAAC
GCTTGACTTTGTGATGAAAAATTGCCTGATGAAATTAGAGAAATCTTTAAATCTCGAGCGCTTGTGTCGATACGC
GCTACTTATACGAATGGCTCTAATAAATAGATGTGCGTGTAAATGCGATGCGTGATAACCGTCTAATTCGATGA
TTTCTGATTTTGACCGAGACCGGTTTTATTATACGGTGGATGAAAAAGCTTTAAACAGCTGGTGGATGAAAAC
CTTACTTCCAATCTCAGTGCAGCGCTCTTTAGTAAAACCGTCTGACGATGCGTACAACCTTTTAATTACGGT
GCTGTTTTGTACCGGTCTTATTTACCAGTTTACGGAAGCAGCTCTTATGGAAGGATGCTGAAAGCAGCTCTT
GGCTCTTATATTCTCAGTGATGAGGTGCTTAAATACCGTACGCTGAAGCAGCTCTTATGGAAGGAGTCTG
```
General Procedures for Synthesis of Acrylamides 5a–5g

To a solution of atropic acid (444 mg, 3.0 mmol) in DCM (6 mL, 0.5 M) at 0 ºC was added oxalyl chloride (0.31 mL, 3.6 mmol) dropwise, followed by catalytic amount of DMF. The resulting colorless solution was then warmed to room temperature and stirred for 2 h, upon which it turned slightly yellow. After cooling to 0 ºC, saturated NaHCO₃ (6 mL) was added, followed by the appropriate amine (4.5 mmol, 1.5 eq) dropwise. The resulting solution was stirred vigorously until a uniform emulsion was obtained at room temperature overnight. The organic and aqueous layers were separated and the aqueous layer was extracted with Et₂O (2 x 5 mL). The combined organic layer was washed with H₂O (5 mL), and brine (5 mL), dried over Na₂SO₄, and concentrated in vacuo. When necessary, purification was performed with silica gel chromatography. Spectral data for 5a–5f are in agreement with those reported in the literature.[2,3,4,5,6]

5g

¹H NMR (500 MHz, CDCl₃): δ 7.46–7.38 (m, 2H), 7.34–7.23 (m, 4H), 7.09–6.98 (m, 3H), 5.70 (s, 1H), 5.47 (s, 1H), 3.81 (s, 2H), 2.74–2.66 (m, 2H), 2.01–1.86 (m, 2H).
\[ ^{13}\text{C NMR (CDCl}_3, 126 \text{ MHz)}: \delta 170.0, 146.2, 138.5, 136.4, 128.6, 128.4, 126.2, 126.0, 125.0, 124.6, 116.9, 45.8, 26.9, 24.0. \]

**General Procedures for Synthesis of Acrylamides 7a–7f**

To a solution of the appropriately-substituted phenylacetic acid (3.0 mmol) in DCM (6 mL) was added oxalyl chloride (0.31 mL, 3.6 mmol) dropwise, followed by catalytic amount of DMF. The resulting colorless solution was then stirred at room temperature for 2 h, upon which it turned slightly yellow. Saturated NaHCO\(_3\) (6 mL) was added, followed by Et\(_2\)NH (4.5 mmol, 1.5 eq) dropwise. The resulting solution was stirred vigorously (uniform emulsion) at room temperature overnight. The organic and aqueous layers were separate and the aqueous layer was extracted with Et\(_2\)O (2 x 5 mL). The combined organic layer was washed with H\(_2\)O (5 mL), and brine (5 mL), dried over Na\(_2\)SO\(_4\), and concentrated \textit{in vacuo}. The resulting oil was used for the next step without further purification.

To a solution of the crude diethylacetamide (1 mmol) in DMF (4 mL) was added Cs\(_2\)CO\(_3\) (977 mg, 3 mmol, 3 eq), HCHO (60 mg, 2 mmol, 2 eq), and tetrabutylammonium bromide (81 mg, 0.25 mmol, 0.25 eq). The resulting suspension was stirred vigorously and heated to 80 °C for 24 h. After cooling to room temperature, the reaction was quenched with H\(_2\)O (5 mL). The organic and aqueous layers were separated and the aqueous layer was extracted with Et\(_2\)O (2 x 5 mL). The combined organic layer was washed with H\(_2\)O (5 mL) and brine (5 mL), dried over Na\(_2\)SO\(_4\), and concentrated \textit{in vacuo}. After a short silica plug eluting with 2:1 hexanes:EtOAc, a pale yellow oil was obtained which was pure enough to be used for the next step without purification. Spectral data for 7c and 7d are in agreement with those reported in the literature.\(^7\)

\(7a\) (Yield = 86%)

\[ ^1\text{H NMR (500 MHz, CDCl}_3): \delta 7.27–7.23 \text{ (m, 4H)}, 5.68 \text{ (s, 1H)}, 5.31 \text{ (s, 1H)}, 3.52 \text{ (q, } J = 7.1 \text{ Hz, 2H)}, 3.23 \text{ (q, } J = 7.1 \text{ Hz, 2H)}, 2.36 \text{ (s, 3H)}, 1.23 \text{ (t, } J = 7.1 \text{ Hz, 3H)}, 1.02 \text{ (t, } J = 7.1 \text{ Hz, 3H)}. \]

\[ ^{13}\text{C NMR (CDCl}_3, 126 \text{ MHz)}: \delta 170.4, 145.9, 138.4, 135.9, 129.4, 128.7, 126.4, 122.9, 112.9, 42.9, 38.9, 21.5, 14.1, 12.9. \]
7b (Yield = 81%)

$^1$H NMR (500 MHz, CDCl$_3$): $\delta$ 7.32 (d, $J = 8.2$ Hz, 2H), 7.15 (d, $J = 8.0$, 2H), 5.65 (s, 1H), 5.26 (s, 1H), 3.49 (dq, $J = 7.7$, 6.7 Hz, 2H), 3.22 (dq, $J = 7.7$, 6.7 Hz, 2H), 2.35 (s, 3H), 1.21 (td, $J = 7.2$, 0.9 Hz, 3H), 1.00 (td, $J = 7.1$, 0.8 Hz, 3H).

$^{13}$C NMR (CDCl$_3$, 126 MHz): $\delta$ 170.5, 145.7, 138.5, 133.2, 129.6, 125.7, 112.13, 42.9, 38.9, 21.3, 14.1, 12.9.

7e (Yield = 91%)

$^1$H NMR (500 MHz, CDCl$_3$): $\delta$ 7.64–7.61 (m, 2H), 7.59–7.55 (m, 2H), 5.79 (s, 1H), 5.46 (s, 1H), 3.53 (q, $J = 7.1$ Hz, 2H), 3.24 (q, $J = 7.1$ Hz, 2H), 1.24 (t, $J = 7.1$ Hz, 3H), 1.04 (t, $J = 7.1$ Hz, 3H).

$^{13}$C NMR (CDCl$_3$, 126 MHz): $\delta$ 169.5, 144.6, 139.5, 130.4 (q, $J = 32.2$ Hz), 126.1, 125.9 (q, $J = 3.8$ Hz), 124.1 (q, $J = 272.8$ Hz), 115.3, 43.0, 39.1, 14.2, 12.9.

7f (Yield = 85%)

$^1$H NMR (500 MHz, CDCl$_3$): $\delta$ 7.91–7.77 (m, 4H), 7.64 (dd, $J = 8.5$, 1.9 Hz, 1H), 7.55–7.44 (m, 2H), 5.84 (s, 1H), 5.43 (s, 1H), 3.57 (q, $J = 7.1$ Hz, 2H), 3.26 (q, $J = 7.1$ Hz, 2H), 1.28 (t, $J = 7.1$ Hz, 3H), 1.02 (t, $J = 7.1$ Hz, 3H).

$^{13}$C NMR (CDCl$_3$, 126 MHz): $\delta$ 170.4, 145.7, 133.5, 133.4, 133.2, 128.6, 128.5, 127.7, 126.5, 125.3, 123.2, 123.2, 113.5, 42.9, 39.0, 14.2, 12.94.

**Synthesis of acrylate 9**

To a solution of the corresponding ethyl ester (0.5 mmol) in DMF (3 mL) was added paraformaldehyde (1.0 mmol, 2 eq), followed by K$_2$CO$_3$ (0.5 mmol). The resulting suspension was stirred vigorously and heated to 70 ºC overnight. The organic and aqueous layers were separated and the aqueous layer was extracted with Et$_2$O (2 x 5 mL). The combined organic layer was washed with H$_2$O (5 mL), and brine (5 mL), dried over Na$_2$SO$_4$, and concentrated *in vacuo*. After a short silica plug (washing with 2:1 hexanes:EtOAc), a pale yellow oil was obtained which was pure enough to be used for the next step without further purification. Yield = 88%.
Preparative Scale Whole Cell Aerobic Reactions

For characterization purposes, the aerobic reactions were scaled up as follows: Cells (8.5 mL, OD<sub>600</sub> = 60) and glucose (1.0 mL, 250 mM) were combined in an unsealed scintillation vial. The olefin substrate was added (0.25 mL, 400 mM in EtOH), followed by EDA (0.25 mM, 400 mM in EtOH). The vial was capped and then shaken at 35 rpm for 5 h. The reactions were quenched by addition of 0.25 mL of 3 M HCl, poured into a Falcon tube, extracted with 1:1 EtOAc:hexanes (7.5 mL), and centrifuged (5,000 rpm, 5 min). The organics were collected, and this extraction sequence was repeated once. The organics were combined, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The crude product was purified via semi-preparative HPLC, with the exception of 10, which was purified by silica gel chromatography (1:1 Hexanes:DCM to 100% DCM).

Characterization Data for Cyclopropanes

6a

1H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36–7.20 (m, 5H), 4.19 (ddt, J = 7.2, 5.4, 2.6 Hz, 2H), 2.94 (s, 3H), 2.90 (s, 3H), 2.43 (dd, J = 8.3, 6.3 Hz, 1H), 2.14 (dd, J = 6.4, 4.9 Hz, 1H), 1.51 (dd, J = 8.4, 5.1 Hz, 1H), 1.28 (td, J = 7.2, 1.8 Hz, 3H).

13C NMR (CDCl<sub>3</sub>, 126 MHz): δ 170.9, 168.5, 138.8, 129.0, 127.4, 126.3, 61.1, 38.8, 37.3, 35.8, 28.9, 21.8, 14.4.

HRMS (m/z): calcd for C<sub>15</sub>H<sub>19</sub>O<sub>3</sub>N, [M+H]<sup>+</sup>, 262.1443; found, 262.1446;


HPLC: Using method described on page SI-4, t<sub>R</sub> (min) = 21.7.

SFC: AS column, 4% IPA, 2.5 mL/min: λ = 210 nm, t<sub>R</sub> (min): major = 6.45, minor = 7.53.

6b

1H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.36–7.20 (m, 5H), 4.39–3.98 (m, 2H), 3.23 (s, 3H), 3.11 (s, 3H), 2.51 (dd, J = 8.6, 6.3 Hz, 1H), 2.09 (t, J = 5.6 Hz, 1H), 1.58 (d, J = 4.4 Hz, 1H), 1.28 (dd, J = 7.8, 6.5 Hz, 3H).

13C NMR (CDCl<sub>3</sub>, 126 MHz): δ 171.4, 138.8, 128.7, 127.8, 127.5, 110.2, 61.1, 60.8, 38.9, 33.6, 26.4, 20.8, 14.3.

HRMS (m/z): calcd for C<sub>15</sub>H<sub>19</sub>O<sub>4</sub>N, [M+H]<sup>+</sup>, 278.1392; found, 278.1398;


HPLC: Using method described on page SI-4, t<sub>R</sub> = 23.9 min.
SFC: OD column, 10% IPA, 2.5 mL/min: $\lambda = 210$ nm, $t_R$ (min): major = 3.88, minor = 4.40.

6c

$^1$H NMR (500 MHz, CDCl$_3$): $\delta$ 7.36–7.20 (m, 5H), 4.19 (qd, $J = 7.1, 1.9$ Hz, 2H), 3.54–3.43 (m, 2H), 3.39–3.28 (m, 1H), 3.29–3.16 (m, 1H), 2.41 (dd, $J = 8.4, 6.2$ Hz, 1H), 2.18 (dd, $J = 6.2, 4.9$ Hz, 1H), 1.86–1.68 (m, 4H), 1.49 (dd, $J = 8.4, 4.9$ Hz, 1H), 1.29 (t, $J = 7.1$ Hz, 3H).

$^{13}$C NMR (CDCl$_3$, 126 MHz): $\delta$ 171.0, 166.8, 138.6, 128.9, 127.4, 126.7, 61.1, 46.6, 46.4, 40.1, 28.3, 26.2, 24.2, 21.2, 14.4.

HRMS ($m/z$): calcd for C$_{17}$H$_{21}$O$_3$N, [M+H]$^+$, 288.1600; found, 288.1591;

GC: Using method described on page SI-4, $t_R$ (min): cis = 10.51, trans = 10.60.

HPLC: Using method described on page SI-4, $t_R$ = 23.5 min.

SFC: AS column, 10% IPA, 2.5 mL/min: $\lambda = 210$ nm, $t_R$ (min): major = 5.12, minor = 6.54.

6d

$^1$H NMR (500 MHz, CDCl$_3$): $\delta$ 7.36–7.20 (m, 5H), 4.26–4.11 (m, 2H), 3.83–3.66 (m, 1H), 3.51 (ddd, $J = 13.3, 6.7, 3.8$ Hz, 1H), 3.45–3.32 (m, 1H), 3.25 (ddd, $J = 13.3, 8.2, 3.6$ Hz, 1H), 2.46 (dd, $J = 8.4, 6.2$ Hz, 1H), 2.16 (dd, $J = 6.2, 4.9$ Hz, 1H), 1.59–1.45 (m, 4H) 1.50 (dd, $J = 8.3, 5.0$ Hz, 1H), 1.29 (t, $J = 7.1$ Hz, 3H), 1.26–1.09 (m, 2H).

$^{13}$C NMR (CDCl$_3$, 126 MHz): $\delta$ 170.9, 166.9, 139.1, 128.9, 127.3, 126.4, 61.1, 46.7, 43.3, 38.8, 28.5, 25.7, 25.5, 24.6, 21.7, 14.4.

HRMS ($m/z$): calcd for C$_{18}$H$_{23}$O$_3$N, [M+H]$^+$, 302.1756; found, 302.1770;


HPLC: Using method described on page SI-4, $t_R$ = 27.4 min.

SFC: AS column, 10% IPA, 2.5 mL/min: $\lambda = 210$ nm, $t_R$ (min): major = 4.06, minor = 4.36.

6e

$^1$H NMR (500 MHz, CDCl$_3$): $\delta$ 7.36–7.20 (m, 5H), 4.45–4.05 (m, 2H), 3.71–3.65 (m, 1H), 3.64–3.55 (m, 3H), 3.51–3.43 (m, 1H), 3.42–3.20 (m, 3H), 2.49 (dd, $J = 8.4, 6.2$ Hz, 1H), 2.16 (dd, $J = 6.2, 4.9$ Hz, 1H), 1.50 (dd, $J = 8.5, 4.9$ Hz, 1H), 1.30 (t, $J = 7.1$ Hz, 3H).

$^{13}$C NMR (CDCl$_3$, 126 MHz): $\delta$ 170.7, 167.4, 138.5, 129.1, 127.6, 126.2, 66.8, 66.3, 61.3, 46.3, 42.7, 38.4, 28.3, 21.7, 14.4.
HRMS (m/z): calcd for C_{17}H_{21}O_{4}N, [M+H]^+; 304.1549; found, 304.1538.

GC: Using method described on page SI-4, t_R (min): cis = 10.60, trans = 10.77.

HPLC: Using method described on page SI-4, t_R (min) = 21.0.

SFC: AS column, 5% IPA, 2.5 mL/min: λ = 210 nm, t_R (min): major = 5.98, minor = 6.47.

6f

^1^H NMR (500 MHz, CDCl_3): δ 7.40–7.18 (m, 6H), 7.14–7.09 (m, 2H), 6.94–6.82 (m, 2H), 4.23 (q, J = 7.2 Hz, 2H), 3.27 (s, 3H), 1.97 (t, J = 7.3 Hz, 1H), 1.73 (t, J = 5.9 Hz, 1H), 1.37–1.25 (m, 4H).


HRMS (m/z): calcd for C_{20}H_{21}O_{3}N, [M+H]^+; 324.1600; found, 324.1596.

GC: Using method described on page SI-4, t_R (min): cis = 10.94, trans = 11.11.

HPLC: Using method described on page SI-4, t_R (min) = 30.8.

SFC: OD column, 10% IPA, 2.5 mL/min: λ = 210 nm, t_R (min): major = 6.27, minor = 7.09.

6g

^1^H NMR (500 MHz, C_6D_6, 25 °C): δ 8.49 (brs, 1H), 7.59–6.70 (m, 8H), 4.14–3.89 (m, 2H), 3.20 (brs, 1H), 2.70–1.83 (brm, 3H), 2.24 (dt, J = 15.8, 6.6 Hz, 1H), 1.41–1.06 (brm, 1H), 1.24 (dd, J = 8.2, 5.4 Hz, 1H), 0.97 (t, J = 7.1 Hz, 3H).

^1^H NMR (500 MHz, C_6D_6, 65 °C): δ 7.68 (brs, 1H), 7.36 (d, J = 7.7 Hz, 2H), 7.12–6.81 (m, 6H), 4.15–3.92 (m, 3H), 3.29 (dt, J = 12.6, 5.8 Hz, 1H), 2.47 (dd, J = 15.2, 7.6 Hz, 1H), 2.31 (dt, J = 15.8, 6.6 Hz, 1H), 2.12–2.21 (m, 1H), 1.95 (brs, 1H), 1.67 (brs, 1H), 1.37–1.31 (m, 1H), 1.29 (dd, J = 8.2, 5.4 Hz, 1H), 1.04 (t, J = 7.1, 3H).

^1^3^C NMR (C_6D_6, 126 MHz): δ 170.8, 167.7, 146.9, 139.9, 129.0, 128.6, 127.3, 126.9, 126.0, 125.4, 124.9, 61.0, 44.4, 39.7, 26.9, 23.8, 21.6, 14.3.

HRMS (m/z): calcd for C_{22}H_{23}O_{3}N, [M+H]^+; 350.1756; found, 350.1760.


HPLC: Using method described on page SI-4, t_R (min) = 35.6.

SFC: OD column, 10% IPA, 2.5 mL/min: λ = 210 nm, t_R (min): major = 10.17, minor = 11.21.
8a

**'H NMR (500 MHz, CDCl₃):** \(\delta 7.20 \text{ (t, } J = 7.6 \text{ Hz, 1H)}, \ 7.14 \text{ (td, } J = 1.6, 0.7 \text{ Hz, 1H)}, \ 7.07 \text{ (dddt, } J = 12.6, 7.5, 1.8, 1.0 \text{ Hz, 2H), 4.18 \text{ (qd, } J = 7.2, 1.1 \text{ Hz, 2H), 3.59–3.41 \text{ (m, 2H), 3.19 \text{ (ddq, } J = 38.7, 14.2, 7.1 \text{ Hz, 2H), 2.43 \text{ (dd, } J = 8.4, 6.2 \text{ Hz, 1H), 2.33 \text{ (s, 3H), 2.17 \text{ (dd, } J = 6.2, 4.9 \text{ Hz, 1H), 1.48 \text{ (dd, } J = 8.4, 4.9 \text{ Hz, 1H), 1.29 \text{ (t, } J = 7.1 \text{ Hz, 3H), 1.10 \text{ (t, } J = 7.1 \text{ Hz, 3H), 0.78 \text{ (t, } J = 7.1 \text{ Hz, 3H).}}

**'C NMR (CDCl₃, 126 MHz):** \(\delta 170.8, 167.9, 139.1, 138.6, 128.8, 128.1, 127.3, 123.4, 61.1, 41.5, 39.4, 39.1, 28.3, 21.5, 21.3, 14.4, 13.2, 12.4.

**HRMS (m/z):** calcd for C₁₈H₂₅O₃N, [M+H]+, 304.1913; found, 304.1917;
**GC:** Using method described on page SI-4, \(t_R\) (min): cis = 9.80, trans = 10.09.
**HPLC:** Using method described on page SI-4, \(t_R\) (min) = 29.8.
**SFC:** AS column, 2% IPA, 2.5 mL/min: \(\lambda = 210 \text{ nm, } t_R\) (min): major = 7.66, minor = 9.24.

8b

**'H NMR (500 MHz, CDCl₃):** \(\delta 7.23–7.17 \text{ (m, 2H), 7.15–7.08 \text{ (m, 2H), 4.18 \text{ (qd, } J = 7.1, 1.6 \text{ Hz, 2H), 3.60–3.36 \text{ (m, 2H), 3.30–3.09 \text{ (m, 2H), 2.41 \text{ (dd, } J = 8.3, 6.2 \text{ Hz, 1H), 2.33 \text{ (s, 3H), 2.16 \text{ (dd, } J = 6.2, 4.9 \text{ Hz, 1H), 1.46 \text{ (dd, } J = 8.4, 4.8 \text{ Hz, 1H), 1.29 \text{ (t, } J = 7.1 \text{ Hz, 3H), 1.09 \text{ (t, } J = 7.1 \text{ Hz, 3H), 0.78 \text{ (t, } J = 7.1 \text{ Hz, 3H).}}}

**'C NMR (CDCl₃, 126 MHz):** \(\delta 170.9, 167.9, 137.0, 136.2, 129.6, 129.0, 128.9, 128.0, 126.4, 61.0, 41.5, 39.4, 38.9, 28.3, 21.2, 21.1, 14.4, 13.2, 12.5.

**HRMS (m/z):** calcd for C₁₈H₂₅O₃N, [M+H]+, 340.1913; found, 340.1917;
**GC:** Using method described on page SI-4, \(t_R\) (min): cis = 9.93, trans = 10.19.
**HPLC:** Using method described on page SI-4, \(t_R\) (min) = 29.9.
**SFC:** AS column, 2% IPA, 2.5 mL/min: \(\lambda = 210 \text{ nm, } t_R\) (min): major = 8.85, minor = 10.47.

8c

**'H NMR (500 MHz, CDCl₃):** \(\delta 7.25 \text{ (d, } J = 8.9 \text{ Hz, 2H), 6.85 \text{ (d, } J = 8.9, 2H), 4.17 \text{ (qd, } J = 6.3, 5.5, 3.4 \text{ Hz, 2H), 3.80 \text{ (s, 3H), 3.54 \text{ (dq, } J = 15.0, 7.5 \text{ Hz, 1H), 3.45 \text{ (dq, } J = 14.1, 7.1 \text{ Hz, 1H), 3.20 \text{ (ddt, } J = 28.0, 14.2, 7.1 \text{ Hz, 2H), 2.37 \text{ (dd, } J = 8.2, 6.3 \text{ Hz, 1H), 2.14 \text{ (dd, } J = 6.3, 4.7 \text{ Hz, 1H), 1.45 \text{ (dd, } J = 8.2, 4.7 \text{ Hz, 1H), 1.29 \text{ (t, } J = 7.1 \text{ Hz, 3H), 1.09 \text{ (t, } J = 7.1 \text{ Hz, 3H), 0.79 \text{ (t, } J = 7.1 \text{ Hz, 3H).}}}

**'C NMR (CDCl₃, 126 MHz):** \(\delta 170.9, 168.0, 159.0, 131.3, 127.9, 114.3, 61.0, 55.5, 41.5, 39.4, 38.6, 28.3, 21.0, 14.4, 13.3, 12.5.
HRMS (m/z): calcd for C_{18}H_{25}O_{4}N, [M+H]^+, 320.1862; found, 320.1866;

GC: Using method described on page SI-4, t_R (min): cis = 10.56, trans = 10.84.

HPLC: Using method described on page SI-4, t_R (min) = 26.6.

SFC: AS column, 4% IPA, 2.5 mL/min: λ = 210 nm, t_R (min): major = 6.49, minor = 7.50.

8d

^{1}H NMR (500 MHz, CDCl_3): δ 7.35–7.21 (m, 4H), 4.18 (qd, J = 7.1, 1.6 Hz, 2H), 3.58–3.36 (m, 2H), 3.21 (ddq, J = 37.3, 14.2, 7.1 Hz, 2H), 2.38 (dd, J = 8.4, 6.2 Hz, 1H), 2.18 (dd, J = 6.3, 5.0 Hz, 1H), 1.47 (dd, J = 8.4, 5.0 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.1 Hz, 3H), 0.82 (t, J = 7.1 Hz, 3H).

^{13}C NMR (CDCl_3, 126 MHz): δ 170.5, 167.4, 137.8, 133.3, 130.2, 129.1, 128.6, 128.0, 61.2, 41.5, 39.5, 38.5, 28.5, 21.2, 14.4, 13.3, 12.4.

HRMS (m/z): calcd for C_{17}H_{22}O_{3}ClN, [M+H]^+, 324.1366; found, 324.1368;

GC: Using method described on page SI-4, t_R (min): cis = 10.29, trans = 10.56.

HPLC: Using method described on page SI-4, t_R (min) = 31.1.

SFC: AS column, 4% IPA, 2.5 mL/min: λ = 210 nm, t_R (min): major = 5.47, minor = 5.91.

8e

^{1}H NMR (500 MHz, CDCl_3): δ 7.62–7.56 (m, 2H), 7.47–7.36 (m, 2H), 4.20 (qd, J = 7.1, 1.1 Hz, 2H), 3.60–3.42 (m, 2H), 3.22 (ddq, J = 43.6, 14.2, 7.1 Hz, 2H), 2.45 (dd, J = 8.4, 6.3 Hz, 1H), 2.24 (dd, J = 6.3, 5.1 Hz, 1H), 1.54 (dd, J = 8.5, 5.1 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.11 (t, J = 7.1 Hz, 3H), 0.82 (t, J = 7.1 Hz, 3H).

^{13}C NMR (CDCl_3, 126 MHz): δ 170.3, 167.1, 143.4, 129.8 (q, J = 32.7 Hz), 126.9, 125.9 (q, J = 3.7 Hz), 124.1 (q, J = 271.9 Hz), 61.3, 41.5, 39.6, 38.7, 28.8, 21.4, 14.3, 13.3, 12.4.

HRMS (m/z): calcd for C_{18}H_{22}F_{3}O_{3}N, [M+H]^+, 358.1630; found, 358.1635;


HPLC: Using method described on page SI-4, t_R (min) = 31.8.

SFC: AS column, 1% IPA, 2.5 mL/min: λ = 210 nm, t_R (min): major = 6.82, minor = 7.41.

8f

^{1}H NMR (500 MHz, CDCl_3): δ 7.85–7.78 (m, 3H), 7.74 (dt, J = 1.4, 0.7 Hz, 1H), 7.53–7.43 (m, 3H), 4.22 (qd, J = 7.2, 1.0 Hz, 2H), 3.65–3.43 (m, 2H), 3.23 (ddq, J = 28.4, 14.1, 7.0 Hz, 2H), 2.57 (dd, J =
8.4, 6.2 Hz, 1H), 2.26 (dd, J = 6.2, 4.9 Hz, 1H), 1.60 (dd, J = 8.4, 4.9 Hz, 1H), 1.32 (t, J = 7.1 Hz, 3H), 1.12 (t, J = 7.1 Hz, 3H), 0.74 (t, J = 7.1 Hz, 3H).

13C NMR (CDCl₃, 126 MHz): δ 170.8, 167.7, 136.6, 133.5, 132.7, 128.8, 127.9, 127.7, 126.6, 126.2, 125.1, 124.8, 61.2, 41.5, 39.5, 39.3, 28.4, 21.3, 14.4, 13.3, 12.5.

HRMS (m/z): calcd for C₂₁H₂₅O₃N, [M+H]+, 340.1913; found, 340.1917;

GC: Using method described on page SI-4, tₚ (min): cis = 11.63, trans = 12.05.

HPLC: Using method described on page SI-4, tₚ (min) = 32.0.

SFC: AS column, 7% IPA, 2.5 mL/min: λ = 210 nm, tₚ (min): major = 6.02, minor = 6.80.

10

1H NMR (500 MHz, CDCl₃): δ 7.33 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 4.19 (qd, J = 7.1, 2.8 Hz, 2H), 4.15–4.02 (m, 2H), 2.33 (s, 3H), 2.20 (dd, J = 8.5, 6.3 Hz, 1H), 2.08 (dd, J = 6.3, 4.9 Hz, 1H), 1.48 (dd, J = 8.5, 4.9 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H).

13C NMR (CDCl₃, 126 MHz): δ 170.9, 169.9, 137.8, 135.6, 130.6, 129.9, 129.4, 129.2, 61.5, 61.1, 38.9, 28.1, 21.2, 19.0, 14.39, 14.2.

Rᵥ = 0.23 (silica gel, DCM)

HRMS (m/z): calcd for C₁₆H₂₀O₄, [M+H]+, 277.1440; found, 277.1442;

GC: Using method described on page SI-4, tₚ (min): cis = 8.77, trans = 9.00.

SFC: AS column, 1% IPA, 2.5 mL/min: λ = 210 nm, tₚ (min): major = 5.79, minor = 7.63.

References